Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Iterum Therapeutics, lowering the price target to $2.00 from $5.00. Despite initial challenges with ORLYNVAH, the only oral penem for urinary tract infections in the US, McCarthy sees long-term value due to its unique market position. He anticipates increased revenue as payer coverage and formulary placements expand, supported by strategic partnerships with Eversana and Alto Specialty Pharma.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments